L26/P-232 A cost-effectiveness analysis of re-biopsy and post-cryopreservation biopsy in PGT-A cycles
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Bartolacci und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is re-biopsy the most appropriate strategy for blastocysts with preimplantation genetic testing for aneuploidy (PGT-A) no-result, and when should vitrified blastocysts be warmed for PGT-A? Summary answer Re-biopsy and post-cryopreservation biopsy in PGT-A cycles are not universally cost-saving; decisions should be guided by maternal age and the number of available blastocysts. What is known already Excessive embryo manipulation in the context of PGT-A is an ongoing clinical concern, as repeated handling may compromise embryo viability and clinical outcomes. Blastocysts that yield a no-result diagnosis following trophectoderm biopsy due to amplification failure frequently undergo re-biopsy, resulting in double vitrification-warming and double biopsy (DVDB). In addition, some blastocysts are cryopreserved prior to undergoing their first biopsy (DVSB), either to optimise laboratory workflow or because the decision to pursue PGT-A is made later in the treatment course. The cost-effectiveness of DVDB and DVSB strategies remains unexplored but may provide important insights to inform clinical decision-making and case management. Study design, size, duration A deterministic, cohort-based decision-analytic model was developed to compare the cost-effectiveness of (i) re-biopsy (DVDB) and (ii) blastocysts undergoing double vitrification with a single biopsy (DVSB) versus untested blastocyst transfer (UBT) in a hypothetical cohort of 100 patients. The analysis was conducted separately for three countries (center A=Italy, center B=Switzerland, center C=Spain) to account for country-specific costs and differences in healthcare settings (public and private). Cost per LB equaled expected cost divided by LB probability. Participants/materials, setting, methods Age-specific reproductive potential was modeled using a logistic function linking maternal age to embryo euploidy probability, to compare DVDB vs UBT. In the UBT, LB was assumed proportional to age-related euploidy, scaled to the observed LB at the reference age. In the DVDB and DVSB, LB and miscarriage rates were extrapolated from overall literature data, and in UBT were extrapolated at the single center. A stochastic patient-level Monte Carlo model compared DVSB vs UBT. Main results and the role of chance DVSB and DVDB were consistently less effective than UBT in terms of LB, regardless of patient age or number of blastocysts available. However, threshold analysis identifies specific maternal age points (over 39/40 years) varying according to the blastocysts number (1-8) beyond which DVSB and DVDB becomes cost-saving. In the center A, UBT was more cost-effective than DVSB when 1-2 blastocysts were available in women up to 38 years, and when 3-8 blastocysts were available up to 39 years. The comparison between DVDB and UBT showed that UBT was more cost-effective in women up to 39 years (n = 1 blastocyst). In the center B, UBT was more cost-effective than DVSB when 1-6 blastocysts were available in women up to 38 years, and when 7-8 blastocysts were available up to 39 years. The comparison between DVDB and UBT showed that UBT was more cost-effective in women up to 40 years (n = 1 blastocyst). In the center C, UBT was more cost-effective when 1-4 blastocysts were available in women up to 40 years, and when 5-8 blastocysts were available up to 41 years. The comparison between DVDB and UBT showed that UBT was more cost-effective in women up to 40 years (n = 1 blastocyst). Limitations, reasons for caution A potential limitation of the study is that the cost estimates are centre-specific and depend on whether the institution is public or private, which may limit generalisability. However, to mitigate this issue, data from three public and private centres in different countries were included. Wider implications of the findings Our findings support a more individualized and economically sustainable use of PGT-A-related interventions, showing that additional embryo manipulations should not be considered routine. Rather, maternal age and the number of available blastocysts should guide decisions on re-biopsy or post-cryopreservation biopsy, helping clinics balance outcomes, cost-effectiveness, and laboratory efficiency. Trial registration number No
Zitieren
APA
Bartolacci, A., Makieva, S., Leeners, B., Arroyo, G., Papaleo, E., & Pagliardini, L. (2026). L26/P-232 A cost-effectiveness analysis of re-biopsy and post-cryopreservation biopsy in PGT-A cycles. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.568
Vancouver
Bartolacci A, Makieva S, Leeners B, Arroyo G, Papaleo E, Pagliardini L. L26/P-232 A cost-effectiveness analysis of re-biopsy and post-cryopreservation biopsy in PGT-A cycles. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.568
BibTeX
@article{Bartolacci2026,
author = {Bartolacci, A. and Makieva, S. and Leeners, B. and Arroyo, G. and Papaleo, E. and Pagliardini, L.},
title = {L26/P-232 A cost-effectiveness analysis of re-biopsy and post-cryopreservation biopsy in PGT-A cycles},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.568}
}
EUVIMED